吸入糖皮质激素治疗稳定期COPD疗效观察被引量：2

The Therapeutic Effects of Inhaling Glucocorticoid in Patients with Stable COPD

导出

摘要目的稳定期慢性阻塞性肺病(COPD)患者吸入糖皮质激素治疗后,观察病情发展状况,探讨糖皮质激素治疗稳定期COPD的疗效.方法采用随机数字法将稳定期慢性阻塞性肺疾病(COPD)患者分为两组,实验组为在常规治疗基础上吸入糖皮质激素布地奈德,对照组仅采用常规治疗,疗程均半年.结果实验组呼吸困难评分、6 min步行距离、生活质量评分、第1秒用力呼气等指标均较对照组明显改善(P<0.05),且急性加重患者的门诊和住院人次较对照组少(P<0.05).结论吸入中等量糖皮质激素布地奈德可减轻稳定期COPD患者的临床症状,改善活动耐力、生活质量和肺功能,减少急性加重次数. Objective To explore therapeutic effect of glucocorticoid in treating chronic obstructive pulmonary disease （COPD） in stable phase, the patients with COPD were treated by by inhaling glucocorticoid in clinical research. Methods The patients with COPD in stable phrase was divided into two groups at random： the experimental group for inhaling glucocorticoid in the conventional treatment bases, and the control group with conventional treatment. The treatment course is both half a year. Results Compared with control group, the dyspneic respiration grade, 6 min walking distance, quality of life grades and the 1 st second forced expiration was improved obviously in the experimental group （P 〈 0.05 ）. The number of out-patient clinic and hospitalization patients with acute exacerbation also decreased （P 〈 0.05）. Conclusions Glucocorticoid can relieve COPD patient＇ s clinical symptom in stable phrase, improve activity endurance, the quality of life and the lung function, and reduce the number of acute outbreak.

作者陶樱刘佳张佩军李岩李力燕

机构地区曲靖市第一人民医院昆明医学院神经科学研究所昆明医学院第二附属医院昆明医学院第一附属医院

出处《昆明医学院学报》 2008年第2期112-114,共3页 Journal of Kunming Medical College

关键词糖皮质激素类慢性阻塞性肺疾病功能改善 Glucocorticoid Chronic obstructive pulmonary diseases Function improving

分类号 R563 [医药卫生—呼吸系统]

引文网络
相关文献

参考文献7

1慢性阻塞性肺疾病诊治指南[J].中华结核和呼吸杂志,2002,25(8):453-460. 被引量：5092
2CELLI B R, MACNEE W. ATS/ERS task force standards for the diagnosis and treatment of patients with COPD:a summary of the ATS/ERS position paper[J ]. Eur Respir J, 2004,23(6) :923 - 946.
3王宋平,熊瑛,王鸿程.慢性阻塞性肺疾病的发病机制[J].临床肺科杂志,2005,10(4):521-522. 被引量：45
4PAUWELS R,LOFDAHL C,LAITINEN L,et al. Long term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking[J]. N Engl J Med, 1999,340(25) : 1948-1954.
5VESTBO J,SORENSENT,LANGE P,et al. Long-term effectof inhaled budesonide in mild and moderate chronic obstructive pulmonary disease:A randomized controlled trial[J], lance, 1999,353(9167) :1819- 1826.
6THE LUNG HEALTH RESEARCH GROUP. Effect of inhaler triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease[J]. N Engl J Meal,2000,343(26) : 1902 - 1913.
7BURGE P,CALVERLEY P,JONES P,et al. Randomized, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease:the ISOLDE trial [J]. Brit Med J, 2000,320(7245 ) : 1297 - 1303.

二级参考文献20

1Pesci A, Balbi B, Majori M, et al. Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease. Eur Respir J, 1998,12: 380-386.
2Turato G, LuinR, Miniati M, et al. Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema, Am J Respir crit car Med,2002,116105-110.
3Saetta M,Baraldo S,corbino L,et al, CD8+ve cells in the lungs of smokers,with chronic obstructive pulmonary disease[J], Am J Respir Crit care Med,1999,160:711-717.
4O'shoughnessy TC, Ansari TW, Barnes NC, et al. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T-lymphocytes with FEV1. Am J Respir Crit Care Med,1997,155:852-857.
5Retamales I, Elliott WM, Meshi B, et al. Amplification of inflammation in emphysema and its association with latent adenoviral infection, Am J Respir Crit Care Med, 2001,164:469-473.
6Mikami M ,Llewellyn-Jones CG, Bayley D,et al. The chemotactic activity of sputum from patients with bronchiectasis. Am J Respic Crit Care Med, 1998,157:732-728.
7Fabbri, LM, Romagnoli M, Corbetta L, et al. Differences in airway inflammation in patients with fixed airflow obstruction due to ashma or chronic obstructive pulmonary disease. Am J Respir Crie Care Med,2003,167:418-424.
8Saetta M,Turato G. Mactrelli P,et al. cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med,2001,163:1304-1309.
9Barnes PJ. Mechanisms in COPD:difference from astma. Chest,2000,163:1304-1309.
10Lomas DA,Mahadeva R. Alpha 1 antitrypsin polymerisation and the serpinopathies:pathobiology and prospects for treatment. J Clin Invest,2002,110:1585-1590.